№ lp_1_27329
File format: docx
Character count: 8242
File size: 79 KB
The document provides a protocol for verifying the successful performance of the iSeq 100 System, detailing the procedures for performance qualification after major repairs or maintenance.
Year:
2018
Region / City:
Not specified
Topic:
Performance Qualification for Sequencing System
Document Type:
Protocol
Organization / Institution:
Illumina, Inc.
Author:
Illumina, Inc.
Target Audience:
Illumina certified personnel
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2016
Region / City:
London, Swindon, Berkshire, Merseyside, Yorkshire, Sunderland
Topic:
Clostridium difficile infection, hospital infection control
Document Type:
Research article
Organization:
Guy’s & St Thomas’ NHS Foundation Trust, Great Western Hospitals NHS Foundation Trust, Heatherwood and Wexham Park Hospitals NHS Foundation Trust, St Helens & Knowsley Hospitals NHS Trust, Calderdale & Huddersfield NHS Foundation Trust, City Hospitals Sunderland NHS Foundation Trust
Author:
Not specified
Target Audience:
Healthcare professionals, researchers
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
A research article detailing the comparison of C. difficile infection control measures across six hospitals in England using whole-genome sequencing to track transmission patterns.
Year:
Annually
Region / City:
United States (CDC)
Topic:
Healthcare-Associated Infections, Antimicrobial Resistance
Document Type:
Report
Organ / Institution:
Centers for Disease Control and Prevention (CDC)
Author:
Not specified
Target Audience:
Funded laboratories, public health officials
Period of Validity:
Annual
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / city:
Montclair, NJ
Topic:
DNA sequencing protocol
Document type:
Standard Operating Protocol (SOP)
Institution:
Montclair State University, Biology Department
Author:
Adam Parker
Target audience:
Laboratory technicians, researchers
Effective period:
Ongoing
Approval date:
8/22/2024
Revision date:
N/A
Year:
2015
Region / City:
N/A
Theme:
Molecular Ecology, Fungal Studies
Document Type:
Research Protocol
Organization:
Kennedy Lab
Authors:
Nhu Nguyen, Peter Kennedy
Target Audience:
Researchers in molecular ecology and fungal studies
Effective Period:
N/A
Approval Date:
N/A
Date of Changes:
April 22, 2015
Year:
2026
Region / City:
N/A
Topic:
Genetic Testing, Exome Sequencing
Document Type:
Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, medical practitioners
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2021
Region / city:
UK
Theme:
Carbon Capture, Usage and Storage (CCUS), Environmental Policy
Document Type:
Project Plan, Government Report
Organization / institution:
Department for Business, Energy and Industrial Strategy (BEIS)
Author:
BEIS (Department for Business, Energy and Industrial Strategy)
Target audience:
Power CCUS Project applicants, governmental and regulatory bodies
Action period:
2021–2030
Approval date:
Not specified
Revision date:
Not specified
Year:
2019-2020
Region / City:
Shanghai, China
Field:
Medical research, oncology
Document type:
Research article
Institution:
Zhongshan Hospital Fudan University
Authors:
Not specified
Target audience:
Researchers, medical professionals
Study period:
May 2019 - February 2020
Approval date:
B2019-060R
Follow-up end date:
March 31, 2020
Year:
2002
Region / city:
Canada
Theme:
Molecular biology
Document type:
Scientific research data
Organization / institution:
Jones et al.
Author:
Jones et al.
Target audience:
Researchers in molecular biology
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2018
Region / City:
San Diego, California
Topic:
Genetic testing, Whole Genome Sequencing, Clinical Genetics
Document Type:
Medical Necessity Letter
Target Audience:
Medical professionals, insurance providers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Note:
Region / City
Topic:
Legacy investigation case sequencing
Document Type:
Policy
Organization / Institution:
Legacy Investigation Branch
Author:
Deputy Head of Legacy Investigation Branch
Review Frequency:
Annually
Year:
2023
Region/City:
Hopewell
Topic:
Early Childhood Education, Story Sequencing
Document Type:
Lesson Plan
Institution:
Hopewell Elementary
Author:
Caitlin Donohue
Target Audience:
Preschool students
Effective Date:
2023-09-01
Date of Approval:
2023-09-01
Section:
Supplemental Materials
Abbreviations:
IOP; MEE/RHC; QC; GSA; PCA; LD; MAF; PC; WES; BAM; VCF; EUR; AFR; AMR; EAS; SAS; GQ; SNPs; MAD; GTEx; Non-PAR; Indels; HWE; AB; GWAS; FAME; GC; QTL; eQTL; CLPP; FDR; OHTN; RINT
Methodology:
Whole exome sequencing and statistical genetic analysis
Sequencing Platform:
NovaSeq S4 flow cell (2x151bp)
Library Preparation Kit:
KAPA Hyper Prep with Library Amplification Primer Mix (KK8504)
Capture Kit:
IDT XGen hybridization and wash kit
Custom Bait:
TWIST Biosciences exome bait
Liquid Handling Systems:
Agilent Bravo; Hamilton Starlet
Quantification Method:
qPCR; Invitrogen Quant-It broad range dsDNA assay
Genotyping Platform:
Global Screening Array (GSA)
Software:
PLINK 1.9; PLINK 2.0; R; Python; Hail v0.2
Reference Panel:
1000 Genomes Project Phase 3
Ancestry Groups:
European (EUR); African (AFR); Admixed American (AMR); East Asian (EAS); South Asian (SAS)
Statistical Analysis:
Analysis of variance (aov in R); Tukey honest significant difference test
Quality Control Criteria:
Sample-level and variant-level QC including genotype missingness, heterozygosity, relatedness (PI_HAT), sex concordance, ancestry inference, BAM and VCF metrics
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2025
Region / City:
[insert local health board name]
Topic:
Community Pharmacy, Common Ailments Service, Docusate Sodium
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
Welsh Medicines Advice Service
Author:
Dianne Burnett
Target Audience:
Pharmacists working within the Common Ailments Service of the Clinical Community Pharmacy Service
Period of Validity:
01 November 2025 - 31 October 2028
Approval Date:
29 August 2025
Review Date:
31 July 2028
Expiration Date:
31 October 2028
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2025
Region / city:
Australia
Subject:
Vocational Education and Training, Health Industry Training
Document type:
Implementation Guide
Organization:
HumanAbility
Author:
HumanAbility, Commonwealth Government through the Department of Employment and Workplace Relations
Target audience:
Registered Training Organisations (RTOs), trainers, assessors, and stakeholders in the VET sector
Period of validity:
September 2025
Approval date:
September 2025
Modification date:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Immunization, Respiratory Syncytial Virus (RSV), Vaccines
Document Type:
Submission
Organization:
SANOFI-AVENTIS AUSTRALIA PTY LTD
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers, immunization program administrators
Period of validity:
From 2024
Approval Date:
24 November 2023
Date of Changes:
17 January 2025
Date of Submission:
7 March 2024
Note:
Contextual Description